Matching slides 303,780
Current window 93,301-93,330
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

93,301-93,330 of 303,780

filter-aware
162
Page 162 of a Form ADV document.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
163
Form ADV page 163, listing specific asset management fee structures.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
164
Page 164 of a Form ADV document.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
165
The slide presents fee structures for U.S. Equity and Global/Non-U.S. Equity strategies, including specific footnotes regarding tracking error assumptions.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
166
Form ADV disclosure page showing tiered fee structures based on assets under management.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
167
Form ADV disclosure page 167.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
170
Form ADV disclosure document page 170.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
171
This appears to be a page from a regulatory filing (Form ADV).asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
172
asset and wealth management mnasset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
174
This is a standard regulatory brochure supplement (Form ADV Part 2B).asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
175
Standard regulatory disclosure document (Form ADV Part 2B).asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
177
This is a standard ADV Part 2B brochure supplement.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
179
This is a standard GLBA (Gramm-Leach-Bliley Act) privacy notice format.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
180
Standard financial privacy notice format.asset and wealth management mn · Goldman Sachs
Consulting deck Equity research 1 hit
01
Slide 1
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
02
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
03
The slide uses a list of callout boxes to highlight key company milestones and financial status.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
04
The slide uses a timeline-based visualization to show the status of drug development programs.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
05
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
06
The slide uses a horizontal process-like flow to present key metrics.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
07
The slide emphasizes the bioerodible nature and small size of the insert compared to legacy technology.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
10
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
11
The slide uses a four-column layout to present strategic advantages.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
12
Eyepoint Goldman Sachs June 10 2025Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
13
Includes a callout box regarding LUGANO enrollment status.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
14
The slide uses a timeline framework to track trial progress from Jan 2025 to mid-2026.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
19
The chart compares DURAVYU 2.7mg, 1.3mg, and aflibercept 2mg. A red box highlights the early improvement at Week 4.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
20
The outlier patient missed multiple visits, leading to significant vision loss at week 24.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
21
The chart compares DURAVYU 2.7mg, DURAVYU 1.3mg, and Aflibercept 2mg. The final values at Week 24 are highlighted in a box.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit
22
Includes company logo and copyright/disclaimer footer.Eyepoint Goldman Sachs June 10 2025 · EyePoint Pharmaceuticals
Consulting deck Equity research 1 hit